Predictors of the rise in vWF after ST elevation myocardial infarction: implications for treatment strategies and clinical outcome: An ENTIRE-TIMI 23 substudy.

AIMS Prior studies suggest that acute coronary syndromes (ACSs) are associated with endothelial activation and that this is of prognostic significance. We hypothesized that endothelial activation, as measured by a rise in von Willebrand Factor (DeltavWF), was influenced by the thrombolysis in myocardial infarction flow grade (TFG), the corrected TIMI frame count (CTFC) and the choice of anticoagulant therapy after fibrinolysis in ST elevation myocardial infarction (STEMI). METHODS AND RESULTS Data were drawn from the enoxaparin and tenecteplase tissue plasminogen activator (TNK-tpa) with or without GPIIb/IIIa inhibitor as the reperfusion strategy in the STEMI trial (ENTIRE-TIMI 23). Three hundred and fourteen patients had serial measurements of vWF (baseline and 48-72 h) and angiographic data available. TFG<3 (P=0.0042) or CTFC>/=40 at 60 min (P=0.0035) were associated with a higher DeltavWF. DeltavWF >/=75th percentile was associated with a higher incidence of death or myocardial infarction (MI) at 30 days, compared with <75th percentile (11.2 vs. 4.1%, P=0.027). Enoxaparin independently reduced the DeltavWF (P=0.019) and also the composite of death or MI (OR 0.33, 95% CI 0.12-0.91, P=0.03) compared with unfractionated heparin. CONCLUSION In STEMI treated by fibrinolysis, coronary flow at 60 min and choice of adjunctive anticoagulant appear to be independent determinants of DeltavWF. Enoxaparin is independently associated with a reduction in DeltavWF and a reduction in death or MI. The clinical benefits of enoxaparin as an adjunctive treatment in STEMI may be mediated in part by a reduction in vWF release.

[1]  E. Vicaut,et al.  Effects of various anticoagulant treatments on von Willebrand factor release in unstable angina. , 2000, Journal of the American College of Cardiology.

[2]  R. Ware,et al.  A human chimera for von Willebrand disease following bone marrow transplantation. , 1993, The American journal of pediatric hematology/oncology.

[3]  J. Pearson,et al.  Endothelial cell function and thrombosis. , 1994, Bailliere's best practice & research. Clinical haematology.

[4]  H. Heidbuchel,et al.  Enoxaparin as Adjunctive Antithrombin Therapy for ST-Elevation Myocardial Infarction: Results of the ENTIRE-Thrombolysis in Myocardial Infarction (TIMI) 23 Trial , 2002, Circulation.

[5]  E. Vicaut,et al.  Early increase of von Willebrand factor predicts adverse outcome in unstable coronary artery disease: beneficial effects of enoxaparin. French Investigators of the ESSENCE Trial. , 1998, Circulation.

[6]  D. Fass,et al.  Transplantation of normal bone marrow into a pig with severe von Willebrand's disease. , 1986, The Journal of clinical investigation.

[7]  O. Alfieri,et al.  Oxidative stress during reperfusion of human hearts: potential sources of oxygen free radicals. , 1995, Cardiovascular research.

[8]  E. Braunwald,et al.  Six- and twelve-month follow-up of the phase I Thrombolysis in Myocardial Infarction (TIMI) trial. , 1988, The American journal of cardiology.

[9]  C. McCollum,et al.  Relationship between endothelial cell markers and arterial stenosis in peripheral and carotid artery disease. , 2000, Thrombosis research.

[10]  F. Depasse,et al.  Comparison of the effect of fondaparinux and enoxaparin on thrombin generation during in-vitro clotting of whole blood and platelet-rich plasma , 2004, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

[11]  E. Vicaut,et al.  Acute Release of Plasminogen Activator Inhibitor-1 in ST-Segment Elevation Myocardial Infarction Predicts Mortality , 2003, Circulation.

[12]  D. Wagner,et al.  von Willebrand factor and the endothelium. , 1991, Mayo Clinic proceedings.

[13]  M. Samama,et al.  Inhibition of factor VIIa generation and prothrombin activation by treatment with enoxaparin in patients with unstable angina * , 2003, British journal of haematology.

[14]  J. Pearson.  Normal endothelial cell function , 2000, Lupus.

[15]  C M Gibson,et al.  Relationship of TIMI myocardial perfusion grade to mortality after administration of thrombolytic drugs. , 2000, Circulation.

[16]  E. Braunwald,et al.  Relationship between TIMI frame count and clinical outcomes after thrombolytic administration. Thrombolysis In Myocardial Infarction (TIMI) Study Group. , 1999, Circulation.

[17]  K. Coyne,et al.  Randomized Comparison of Enoxaparin, a Low-Molecular-Weight Heparin, With Unfractionated Heparin Adjunctive to Recombinant Tissue Plasminogen Activator Thrombolysis and Aspirin Second Trial of Heparin and Aspirin Reperfusion Therapy (HART II) , 2002 .

[18]  E. Braunwald,et al.  ST segment resolution as a tool for assessing the efficacy of reperfusion therapy. , 2001, Journal of the American College of Cardiology.

[19]  W. Aird,et al.  Thrombin and Phenotypic Modulation of the Endothelium , 2004, Arteriosclerosis, thrombosis, and vascular biology.

[20]  E. Antman,et al.  Abciximab facilitates the rate and extent of thrombolysis: results of the thrombolysis in myocardial infarction (TIMI) 14 trial. The TIMI 14 Investigators. , 1999, Circulation.

[21]  H. S. Mueller,et al.  The Thrombolysis in Myocardial Infarction (TIMI) trial. Phase I findings. , 1985, The New England journal of medicine.

[22]  D. Crossman,et al.  Differential regulation by cytokines of constitutive and stimulated secretion of von Willebrand factor from endothelial cells. , 1990, Blood.

[23]  D. Wagner,et al.  Factor Viii in Wild Type and Von Willebrand Disease Mouse Models Interleukin 11 Significantly Increases Plasma Von Willebrand Factor And , 2022 .

[24]  L. Bouter,et al.  von Willebrand factor, C-reactive protein, and 5-year mortality in diabetic and nondiabetic subjects: the Hoorn Study. , 1999, Arteriosclerosis, thrombosis, and vascular biology.

[25]  T. Mayadas,et al.  von Willebrand factor biosynthesis and partitioning between constitutive and regulated pathways of secretion after thrombin stimulation. , 1989, Blood.

[26]  S. Goto,et al.  Plasma Concentration of von Willebrand Factor in Acute Myocardial Infarction , 2000, Thrombosis and Haemostasis.

[27]  P. Crean,et al.  Early temporal expression of soluble cellular adhesion molecules in patients with unstable angina and subendocardial myocardial infarction. , 1999, The American journal of cardiology.

[28]  D. Ardissino,et al.  Activation of the contact system and inflammation after thrombolytic therapy in patients with acute myocardial infarction. , 2004, The American journal of cardiology.

[29]  M. Roncaglioni,et al.  Early coronary reperfusion blunts the procoagulant response of plasminogen activator inhibitor-1 and von Willebrand factor in acute myocardial infarction. , 1990, Journal of the American College of Cardiology.

[30]  J. Jais,et al.  Elevated circulating E-selectin, intercellular adhesion molecule 1, and von Willebrand factor in patients with severe infection. , 1998, American journal of respiratory and critical care medicine.

[31]  T. Mayadas,et al.  Hypoxia-induced exocytosis of endothelial cell Weibel-Palade bodies. A mechanism for rapid neutrophil recruitment after cardiac preservation. , 1996, The Journal of clinical investigation.

[32]  G. Soff,et al.  The von Willebrand Factor in Myocardial Infarction and Unstable Angina: A Kinetic Study , 1986, Thrombosis and Haemostasis.

[33]  M. Bonneau,et al.  In vivo regulation of von willebrand factor synthesis: von Willebrand factor production in endothelial cells after lung transplantation between normal pigs and von Willebrand factor-deficient pigs. , 1999, Arteriosclerosis, thrombosis, and vascular biology.

[34]  C. Granger,et al.  Low molecular weight heparin (dalteparin) compared to unfractionated heparin as an adjunct to rt-PA (alteplase) for improvement of coronary artery patency in acute myocardial infarction-the ASSENT Plus study. , 2003, European heart journal.

[35]  P. Crean,et al.  Risk stratification in unstable angina and non-Q wave myocardial infarction using soluble cell adhesion molecules , 2001, Heart.

[36]  M. Dillon,et al.  Soluble cell adhesion molecules and von Willebrand factor in children with Kawasaki disease , 1995, Clinical and experimental immunology.

[37]  G. Lip,et al.  Thrombomodulin, von Willebrand factor and E-selectin as plasma markers of endothelial damage/dysfunction and activation in pregnancy induced hypertension. , 2004, Thrombosis research.

[38]  M. Dalby,et al.  Comparison of effects on markers of blood cell activation of enoxaparin, dalteparin, and unfractionated heparin in patients with unstable angina pectoris or non-ST-segment elevation acute myocardial infarction (the ARMADA study). , 2003, The American journal of cardiology.

[39]  G. Hankey,et al.  Endothelial and platelet activation in acute ischemic stroke and its etiological subtypes. , 2003, Stroke.

[40]  E. Braunwald,et al.  TIMI frame count: a quantitative method of assessing coronary artery flow. , 1996, Circulation.